Adamis poised to challenge Mylan's pricey EpiPen with lower-cost Symjepi injection
admin 16th June 2017 Uncategorised 0Mylan’s EpiPen will soon have another lower-cost competitor to contend with. Adamis Pharmaceuticals, whose epinephrine injection was turned back by the FDA last year before the EpiPen pricing controversy erupted, won an agency nod Thursday.
More: Adamis poised to challenge Mylan's pricey EpiPen with lower-cost Symjepi injection
Source: fierce